Drug intelligence / Profile preview

inulin + Streptococcus salivarius

Development stage: Unknown
Lead developer: Universidade de Passo Fundo
Modality: Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Inulin + Streptococcus salivarius is a synbiotic combination therapy investigated for the treatment of halitosis (bad breath). It consists of the prebiotic fiber inulin and the probiotic bacterium *Streptococcus salivarius*. *Streptococcus salivarius* is a natural inhabitant of the human oral cavity, and certain strains are known to produce bacteriocin-like inhibitory substances (BLIS) that inhibit the growth of the bacteria responsible for producing volatile sulfur compounds, the main cause of halitosis. Inulin acts as a prebiotic, selectively promoting the growth of beneficial bacteria like *S. salivarius*. The Universidade de Passo Fundo conducted a Phase 2, randomized, double-blind clinical trial to evaluate the efficacy of this combination in reducing halitosis and tongue coating.

Other names: S salivarius-Universidade de Passo Fundo-halitosis

Beyond the preview

Go deeper on inulin + Streptococcus salivarius.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inulin + Streptococcus salivarius.

Explore the full profile